ClinicalTrials.gg
RecruitingNCT06497985Updated Mar 19, 2026

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

A Phase 3 interventional study of Tucidinostat and Sintilimab in Colorectal Cancer, sponsored by Chipscreen Biosciences, Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing sintilimab in Colorectal Neoplasms — 15 open to participants now, 18 under way, 3 of them phase 3. sintilimab · Colorectal Neoplasms.

Planned enrollment
2nd of 26
430 · median 42
Started
2024
with 4 others
Phase 3
3 of 26
2 open now
Primary completion
2028-05
later than 16 of 17 live
Registered
15th of 26
by date
Lead sponsor
1 of 26
Chipscreen Biosciences, Ltd.

Among the 26 studies testing sintilimab in Colorectal Neoplasms, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2024, is one of 3 in phase 3, reaches primary completion later than 16 of the 17 other live ones, and was the 15th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 26 studies testing sintilimab in Colorectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing sintilimab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

A randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.

Read the detailed description

This is a randomised, open-label, multicenter phase III study evaluating the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients. 430 patients will be randomised (1:1) to receive tucidinostat in combination with sintilimab and bevacizumab (experimental arm) or fruquintinib monotherapy (control arm).

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written for the study.
  2. Age ≥18 years and ≤75 years.
  3. or cytologically confirmed unresectable and colorectal adenocarcinoma.
  4. Has been previously treated and has shown disease progression or could not tolerate standard treatment, which must include fluoropyrimidine, irinotecan and oxaliplatin, with or without an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (bevacizumab) or anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab or panitumumab) .
  5. Have confirmed MSS or MSI-L, or pMMR.
  6. KRAS status must have been previously determined (mutant or wild-type) .
  7. per v1.1.
  8. PS 0 or 1.
  9. Adequate organ function.
  10. Expected survival >12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Prior use of HDAC inhibitor.
  2. Received prior therapies targeting , PD-L1, CTLA4, or any other immune checkpoint pathway.
  3. Prior use of small-molecule tyrosine kinase inhibitor of VEGF receptors.
  4. Received any anti-tumor therapy or agent and device within 28 days before the first dose of study treatment.
  5. Received radiotherapy within 28 days before the first dose of study treatment.
  6. If randomized into the control group, it is planned to use the combination of tucidinostat with PD-1 inhibitor and bevacizumab after the end of study treatment.
  7. History of diseases requiring systemic treatment within 2 years before the first dose of study treatment.
  8. Known history of primary immunodeficiency.
  9. Received systemic drugs within 28 days before the first dose of study treatment.
  10. Received systemic immunostimulatory drugs within 28 days before the first dose of study treatment.
  11. Received major surgery within 28 days before the first dose of study treatment.
  12. Received a within 28 days before the first dose of study treatment or planned to receive during the study period.
  13. Has not recovered ( ≤ Grade 1 defined by V5.0) from AEs due to prior anti-cancer therapy.
  14. Has uncontrolled diabetes assessed by investigators within 7 days before the first dose of study treatment.
  15. Has symptomatic and untreated central nervous system (CNS) .
  16. Has uncontrollable or major cardiovascular disease.
  17. History of cerebrovascular accidents within 6 months before the first dose of study treatment.
  18. History of serious thromboembolism within 6 months before the first dose of study treatment.
  19. History of gastrointestinal perforation and/or fistula etc., within 6 months before the first dose of study treatment.
  20. Obvious gastrointestinal abnormalities during the screening period,which may affect the intake, transport or absorption of drugs.
  21. Known history of bleeding disorders or coagulopathy.
  22. Anticoagulants or thrombolytic agents are being used during the screening period.
  23. Uncontrolled pleural/abdominal/pericardial effusion that was drained within 14 days before the first dose of study treatment.
  24. Suspected interstitial lung disease (ILD) or pulmonary fibrosis or pulmonary inflammation requiring treatment.
  25. Severe or active infection requiring systemic therapy.
  26. Known active pulmonary tuberculosis.
  27. Active or .
  28. positive or syphilis infection.
  29. History of malignant tumor.
  30. History of allogeneic organ transplantation and hematopoietic stem cell transplantation.
  31. History of to study drugs, or any of its .
  32. History of alcohol or drug abuse.
  33. Unwilling or unable to comply with procedures required in this protocol.
  34. Pregnant or breast-feeding women. Male/Female is unwilling or unable to use a highly effective method of .
  35. Any condition not suitable for participating in the trial in the opinion of the Investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    tucidinostat+sintilimab+bevacizumab

    Drug: Tucidinostat · Drug: Sintilimab · Drug: Bevacizumab

  • Active comparator
    fruquintinib

    Drug: Fruquintinib

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    From randomization to the date of death from any cause.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS assessed by investigator per RECIST v1.1, measured from the date of randomization until progression or death, whichever occurs first.

    Time frame: Up to approximately 2 years

  2. Overall response rate (ORR)

    Proportion of participants who achieved complete response (CR) or partial response (PR) assessed by investigator according to RECIST v1.1.

    Time frame: Up to approximately 2 years

  3. Duration of response (DOR)

    From the first occurrence of PR or CR until the date of first documented progression according to RECIST 1.1, or death, whichever occurs first.

    Time frame: Up to approximately 2 years

  4. Disease control rate (DCR)

    Proportion of participants who achieved CR or PR, or stable disease (SD) assessed by investigator according to RECIST v1.1.

    Time frame: Up to approximately 2 years

  5. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score

    EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire, contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale.Change from baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life Scale scores will be presented.

    Time frame: Up to approximately 2 years

  6. Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores

    The EQ-5D-5L is a self-reported health status questionnaire that consisted of 2 components: health state profile and optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problem, slight problem, moderate problem, severe problem, and extreme problem. Change from baseline in health utility index scores will be presented.

    Time frame: Up to approximately 2 years

  7. Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score

    EQ-5D-5L consisted of 2 components: health state profile and optional VAS. The VAS records the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. Change from baseline in EQ-5D-5L VAS scores will be presented.

    Time frame: Up to approximately 2 years

  8. Safety and Tolerability

    Number of Participants Who Experience an Adverse Event (AE) assessed by CTCAE v5.0.

    Time frame: Up to approximately 2 years

  9. Plasma concentrations of tucidinostat

    Plasma samples were collected from the participants at the defined time points. Plasma concentrations were measured using a validated, specific, and sensitive method.

    Time frame: Up to approximately 6 months

07

Study locations

1 of 1 sites recruiting
  • Rui-Hua Xu
    Guangzhou, Guangdong 510050, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for May 2028, 41 months after the start.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's planned 41 months is close to that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 12, 2024
StartActual
Dec 6, 2024
Primary completionEst.
May 31, 2028
CompletionEst.
Sep 30, 2028
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06497985
Responsible party
Sponsor
First posted
Jul 12, 2024
Start date
Dec 6, 2024
Primary completion
May 31, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Mar 19, 2026

Study contacts

Xinhao Wang
Contact
xinhwang@chipscreen.com
+86 0755-36993550
Rui-Hua Xu
Contact
xurh@sysucc.org.cn
Rui-Hua Xu
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucidinostat · Sintilimab

Start the discussion